Procurement of devices for pulsed-field ablation of paroxysmal atrial fibrillation: the experience of the Tuscany region in Italy

Main Article Content

Sabrina Trippoli Maria Rita Romeo Francesca Collini Andrea Messori

Abstract

In this Health Policy article, we describe the experience conducted in Italy in the Tuscany region to implement an appropriate management of the devices available for pulsed-field ablation of paroxysmal atrial fibrillation. For patients who do not respond to pharmacological treatment, ablation techniques have long been a recognized therapeutic standard. Radiofrequency ablation and cryoballoon ablation (both referred to as thermal ablation options) were the first two techniques made available for this therapeutic indication. More recently, pulsed-field ablation has been developed as a means of achieving the same clinical result without any thermal intervention; iIn fact, thermal techniques are more often involved in determining local tissue damages. In 2024, there are already three different devices available to perform pulsed/field ablation, thus minimizing the risk of thermal damage to local tissues. These three devices include Farawave (from Boston), PulseSelect (from Medtronic), and Varipulse (from Johnson & Johnson). 


Our paper reports on the technical characteristics of these three devices and the available clinical evidence on their effectiveness. The clinical studies for Farawave (the first device developed in 2021) are more numerous than those for PulseSelect and Varipulse, whose development is much more recent.


Epidemiological data from the entire region were analysed to determine the total number of the three devices needed by our hospitals on an annual basis. These regional data were interpreted in comparison with the national consumption of these devices.


In conclusion, the main strength of the experience described here is that the principles of HTA have been successfully applied in daily practice. For more than 5 years, this policy has been applied in our Centro Operativo in the management of about 80 devices classified as class IIb, III or active implantable.

Keywords: meta-analysis; Kaplan-Meier curves; Shiny method; IPDFROMKM method; artificial intelligence; reconstructed individual patient data.

Article Details

How to Cite
TRIPPOLI, Sabrina et al. Procurement of devices for pulsed-field ablation of paroxysmal atrial fibrillation: the experience of the Tuscany region in Italy. Medical Research Archives, [S.l.], v. 12, n. 8, aug. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5667>. Date accessed: 04 dec. 2024. doi: https://doi.org/10.18103/mra.v12i8.5667.
Section
Research Articles

References

1. Regione Toscana, Regional Decree no. 8521, 19 April 2024, link:
https://www301.regione.toscana.it/bancadati/atti/DettaglioAttiD.xml?codprat=2024AD00000009452.

2. Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4. PMID: 27042964.

3. Aryana A, Singh SM, Mugnai G, et al. Pulmonary vein reconnection following catheter ablation of atrial fibrillation using the second-generation cryoballoon versus open-irrigated radiofrequency: results of a multicenter analysis. J Interv Card Electrophysiol. 2016 Dec;47(3):341-348. doi: 10.1007/s10840-016-0172-z. Epub 2016 Jul 30. PMID: 27475949.

4. Reddy VY, Gerstenfeld EP, Natale A, et al. Pulsed-field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291. Epub 2023 Aug 27. PMID: 37634148.

5. Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed-field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021 May;7 (5):614-627. doi: 10.1016/j.jacep.2021.02.014. Epub 2021 Apr 28. PMID: 33933412.

6. Della Rocca DG, Marcon L, Magnocavallo M, et al. Pulsed electric field, cryoballoon, and radiofrequency for paroxysmal atrial fibrillation ablation: a propensity score-matched comparison. Europace. 2023 Dec 28;26(1):euae016. doi: 10.1093/europace/euae016. PMID: 38245007; PMCID: PMC10823352.

7. Maurhofer J, Kueffer T, Madaffari A, et al. Pulsed-field vs. cryoballoon vs. radiofrequency ablation: a propensity score matched comparison of one-year outcomes after pulmonary vein isolation in patients with paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2024 Mar;67(2):389-397. doi: 10.1007/s10840-023-01651-4. Epub 2023 Sep 30. PMID: 37776355; PMCID: PMC10902096.

8. Turagam MK, Neuzil P, Schmidt B, et al. Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation. JAMA Cardiol. 2023 Dec 1;8(12): 1142-1151. doi: 10.1001/jamacardio.2023.3752. PMID: 37910101; PMCID: PMC10620676.

9. Metzner A, Fiala M, Vijgen J, et al. Long-term outcomes of the pentaspline pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation: results of the prospective, multicentre FARA-Freedom Study. Europace. 2024 Mar 1;26(3):euae053. doi: 10.1093/europace/euae053. PMID: 38385529; PMCID: PMC10932745.

10. Aldaas OM, Malladi C, Han FT, et al. Pulsed-field ablation versus thermal energy ablation for atrial fibrillation: a systematic review and meta-analysis of procedural efficiency, safety, and efficacy. J Interv Card Electrophysiol. 2024 Apr;67(3):639-648. doi: 10.1007/s10840-023-01660-3. Epub 2023 Oct 19. PMID: 37855992; PMCID: PMC11016003.

11. Verma A, Haines DE, Boersma LV, et al. Pulsed-field ablation for the treatment of atrial fibrillation: PULSED atrial fibrillation pivotal study. Circulation. 2023 May 9;147(19):1422-1432. doi: 10.1161/CIRCULATIONAHA.123.063988. Published 6 March 2023. PMID: 36877118; PMCID: PMC10158608.

12. Duytschaever M, De Potter T, Grimaldi M, et al. Ablation of paroxysmal atrial fibrillation using a novel variable loop biphasic pulsed-field ablation catheter integrated with a three-dimensional mapping system: one-year results of the multicentre InspIRE study. Circ Arrhythm Electrophysiol. 2023 Mar; 16(3):e011780. doi: 10.1161/CIRCEP.122.011780. Published 3 February 2023.

13. Qamar U, Agarwal S, Krishan S, et al. Efficacy and safety of pulsed-field ablation for atrial fibrillation: A systematic review and meta-analysis. Pacing Clin Electrophysiol. 2024 Mar;47(3):474-480. doi: 10.1111/pace.14947. Epub 2024 Feb 11. PMID: 38341625.

14. Messori A, Mamone D, Rivano M, Romeo MR, Vaiani M, Trippoli S. Pulsed-field ablation for paroxysmal atrial fibrillation: An indirect comparison of effectiveness among three proprietary devices conducted in the absence of randomized trials. Int J Cardiol. 2024 Jul 1;406:132025. doi: 10.1016/j.ijcard.2024.132025. Epub 2024 Apr 5. PMID: 38583595.

15. Cheung CC, Nattel S, Macle L, Andrade JG. Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. Can J Cardiol. 2021 Oct;37(10):1607-1618. doi: 10.1016/j.cjca.2021.06.011. Epub 2021 Jun 26. PMID: 34186113.